Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18927508 | Compositions, Systems, and Methods for Modulating a Target Gene | October 2024 | January 2026 | Allow | 15 | 2 | 1 | Yes | No |
| 18782879 | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR | July 2024 | December 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18756256 | HIV INHIBITOR COMPOUNDS | June 2024 | July 2025 | Allow | 13 | 1 | 0 | No | No |
| 18670566 | METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTS | May 2024 | January 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18626740 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | April 2024 | March 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18602126 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | March 2024 | March 2025 | Allow | 12 | 0 | 0 | No | No |
| 18600365 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | March 2024 | June 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18586920 | Pleiotropic Pathway Modifier Compounds and Method of Treating Diseases | February 2024 | September 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18437813 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | February 2024 | July 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18418168 | PYRAZOLO[1,5-C]PYRIDO[3,4-E]PYRIMIDINES AS CK2 INHIBITORS | January 2024 | September 2024 | Allow | 8 | 1 | 0 | No | No |
| 18345461 | USE OF BROMODOMAIN-CONTAINING PROTEIN 9 INHIBITORS TO TREAT AND/OR PREVENT UTERINE LEIOMYOSARCOMA | June 2023 | March 2025 | Allow | 21 | 3 | 0 | Yes | No |
| 18209674 | SOLID FORMS OF JAK INHIBITOR AND PROCESS OF PREPARING THE SAME | June 2023 | October 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18329958 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | June 2023 | June 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18198191 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | May 2023 | April 2025 | Abandon | 23 | 2 | 1 | No | No |
| 18140576 | POLYMORPHS OF [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5-TRIMETHOXYPHENYL)METHANONE AND ITS SALTS | April 2023 | December 2024 | Allow | 20 | 1 | 1 | No | No |
| 18131314 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | April 2023 | October 2024 | Allow | 19 | 2 | 1 | No | No |
| 18125940 | INTRANASAL OLANZAPINE FORMULATIONS AND METHODS OF THEIR USE | March 2023 | August 2024 | Allow | 17 | 2 | 1 | No | No |
| 18028192 | THIADIAZOLONE DERIVATIVES AND THEIR USE AS AMPK AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | March 2023 | January 2026 | Allow | 34 | 0 | 0 | Yes | No |
| 18025817 | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR | March 2023 | January 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 17998552 | Azetidine Cyclic Ureas | November 2022 | February 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 17914324 | PHARMACEUTICAL COMPOSITION COMPRISING PROTEIN KINASE INHIBITOR AND CHEMOTHERAPEUTIC DRUG AND USE THEREOF | September 2022 | February 2026 | Allow | 41 | 1 | 1 | Yes | No |
| 17906582 | CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST | September 2022 | October 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17909283 | SALTS AND POLYMORPHIC FORMS OF 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1-YL)-2-(1,3-DIMETHYL-1H-PYRAZOL-4-YL)-3H-IMIDAZO[4,5-B]PYRIDINE | September 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
| 17822344 | EIF4E INHIBITORS AND USES THEREOF | August 2022 | August 2024 | Allow | 24 | 2 | 1 | No | No |
| 17796160 | COMBINATION DRUG THERAPIES FOR CNS DISORDERS | July 2022 | December 2025 | Allow | 40 | 1 | 1 | No | No |
| 17870476 | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING VIABILITY AND FUNCTION OF CELLS, TISSUES AND ORGANS | July 2022 | May 2025 | Allow | 33 | 3 | 2 | Yes | No |
| 17791755 | MEK INHIBITORS AND THERAPEUTIC USES THEREOF | July 2022 | April 2025 | Allow | 33 | 0 | 0 | No | No |
| 17854801 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | June 2022 | July 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17789623 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | June 2022 | March 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17788663 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | June 2022 | November 2025 | Allow | 41 | 1 | 0 | No | No |
| 17786387 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | June 2022 | September 2025 | Allow | 39 | 2 | 0 | No | No |
| 17779512 | COCRYSTALS OF STEROID AND SECOSTEROID COMPOUNDS AND COMPOSITIONS COMPRISING THEM | May 2022 | November 2025 | Allow | 42 | 1 | 0 | No | No |
| 17749958 | CONJUGATE MONOMETHYL AURISTATIN E TO OBTAIN A COMPOSITION FOR TREATMENT OF PROSTATE CANCER | May 2022 | June 2025 | Allow | 36 | 0 | 0 | No | No |
| 17775876 | Pharmaceutical Formulations for Managing Uric Acid Content in Human Body | May 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17737375 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | May 2022 | October 2025 | Allow | 42 | 1 | 0 | No | No |
| 17773554 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | April 2022 | December 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17772952 | USE OF BILE ACIDS AND DERIVATIVES THEREOF IN PREPARATION OF GPR39 AGONIST | April 2022 | December 2025 | Allow | 43 | 1 | 1 | No | No |
| 17729901 | CRYSTAL FORM I OF CURCUMIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | April 2022 | November 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17767028 | ATF6 MODULATORS AND USES THEREOF | April 2022 | February 2026 | Allow | 47 | 0 | 1 | No | No |
| 17655020 | NOVEL PHARMACEUTICAL COMPOSITIONS | March 2022 | February 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17637755 | COMPOSITIONS FOR SMALL MOLECULE THERAPEUTIC AGENT COMPOUNDS | February 2022 | November 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17637246 | METHODS FOR REDUCING THC CONTENT IN COMPLEX CANNABINOID MIXTURES IN WHICH THC IS A MINOR COMPONENT | February 2022 | September 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17629268 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | January 2022 | December 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17620848 | DEUTERATED 7-(3-(4-(2-([18F]FLUOR)ETHOXY)PHENYL)PROPYL)-2-(FURAN-2-YL)-7H-PYRAZOLO [4,3-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-AMINE DERIVATIVES | December 2021 | August 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17538919 | TIME TO RESOLUTION OF AXITINIB-RELATED ADVERSE EVENTS | November 2021 | June 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17613303 | Pharmaceutical Composition for Alzheimer's Disease | November 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17611053 | COMBINATION THERAPY FOR PROLIFERATIVE CONDITIONS | November 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17595116 | ARYLQUINOZILINE DERIVATIVES AS ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | November 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17607634 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | October 2021 | August 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17606307 | ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | October 2021 | August 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17602426 | ANTIBACTERIAL COMPOUNDS | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17495413 | LIQUID ORAL DOSAGE FORMULATIONS OF METHYLNALTREXONE | October 2021 | September 2025 | Allow | 48 | 2 | 1 | No | No |
| 17601258 | METHODS OF TREATING CHARCOT-MARIE-TOOTH DISEASE | October 2021 | January 2026 | Allow | 52 | 2 | 1 | Yes | No |
| 17437264 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | September 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17436277 | SOLVENT-FREE DENTAL ADHESIVE COMPOSITION | September 2021 | October 2025 | Allow | 50 | 2 | 1 | No | No |
| 17436015 | USE OF 8,9- DIHYDROCANNABIDIOL COMPOUNDS | September 2021 | January 2026 | Allow | 52 | 3 | 1 | No | No |
| 17435803 | Compounds for Treating Neurodegenerative Diseases and Cancers | September 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17435939 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | September 2021 | February 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17435031 | BENZOTHIOPHENE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | August 2021 | January 2025 | Allow | 40 | 1 | 0 | No | No |
| 17412102 | DUAL MAGL AND FAAH INHIBITORS | August 2021 | February 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17428734 | TUFT CELL SPECIFICATION IN INFLAMMATORY ILEITIS | August 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17428953 | TYK2 PSEUDOKINASE LIGANDS | August 2021 | July 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17310164 | HETEROCYCLIC COMPOUNDS AS ANTAGONIST OF NMDA | July 2021 | January 2026 | Allow | 54 | 3 | 1 | Yes | No |
| 17305773 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | July 2021 | October 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17422642 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17422434 | TRANSDERMAL PENETRANT FORMULATIONS CONTAINING CANNABIDIOL | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17422252 | NLRP3 MODULATORS | July 2021 | July 2024 | Allow | 36 | 0 | 1 | Yes | No |
| 17421533 | PALATABLE FORMULATIONS | July 2021 | August 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17421567 | METALLOENZYME INHIBITOR COMPOUNDS | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17366923 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | July 2021 | February 2025 | Allow | 43 | 1 | 1 | No | No |
| 16499771 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | July 2021 | May 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 17419956 | COMBINATION THERAPY OF PHOSPHATE BINDERS AND VITAMIN K | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17415492 | AMINOPYRIMIDINE COMPOUND USED FOR INHIBITING ACTIVITY OF PROTEIN KINASE | June 2021 | January 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17309646 | SALT OF SYK INHIBITOR AND CRYSTALLINE FORM THEREOF | June 2021 | October 2024 | Allow | 40 | 1 | 0 | No | No |
| 17335202 | Use of fumaric acid esters and pharmaceutically acceptable salts thereof in preparing pharmaceuticals for treating ferroptosis-related diseases | June 2021 | December 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17293817 | INHIBITOR OF BRUTON TYROSINE KINASE | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17293268 | NOVEL ADMINISTRATION METHOD | May 2021 | September 2025 | Abandon | 52 | 3 | 1 | Yes | No |
| 17292891 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | May 2021 | April 2025 | Allow | 48 | 1 | 1 | No | No |
| 17292036 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | May 2021 | March 2025 | Allow | 46 | 1 | 1 | No | No |
| 17291416 | FEED ADDITIVE FOR DAIRY CATTLE COMPRISING N-ACETYL-L-TRYPTOPHAN AS ACTIVE INGREDIENT | May 2021 | April 2025 | Abandon | 47 | 2 | 0 | Yes | No |
| 17289736 | PROGNOSIS AND TREATMENT OF METASTATIC CANCER | April 2021 | October 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17244039 | Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases | April 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17289470 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17289062 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | April 2021 | April 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17239086 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | April 2021 | March 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17285840 | PYRIDYLPHENYLAMINOQUINOLINES AND ANALOGUES | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17230009 | PROCESS FOR PREPARING A COMPOUND OF FORMULA (XIII) | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17285214 | COMPOSITION AND METHOD OF STRENGTHENING SKIN BARRIER | April 2021 | March 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17224557 | HIV INHIBITOR COMPOUNDS | April 2021 | April 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17281748 | METHODS FOR THE TREATMENT OF SCLERODERMA | March 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17250938 | NOVEL OXADIAZOLES | March 2021 | June 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17278095 | STEROL PURIFICATION | March 2021 | December 2025 | Abandon | 57 | 3 | 1 | No | Yes |
| 17277954 | SMALL MOLECULE MENIN INHIBITORS | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17276821 | TREATMENT FOR OBESITY | March 2021 | April 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17271202 | BTK INHIBITORS, PHARMACEUTICALLY ACCEPTABLE SALTS, POLYMORPHS AND APPLICATION THEREOF | February 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17268512 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | February 2021 | December 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 16957106 | HOLE TRANSPORT MATERIAL AND SYNTHESIZING METHOD THEREOF | June 2020 | December 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16767306 | ANTITUMOR AGENT, A METHOD OF TREATING TUMOR, AND A METHOD OF ENHANCING AN ANTITUMOR EFFECT OF AN ANTITUMOR AGENT | May 2020 | July 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16646081 | Process for preparing crystalline Tipiracil Hydrochloride | March 2020 | December 2024 | Abandon | 58 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHMIDT, IZABELA MARIA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SCHMIDT, IZABELA MARIA works in Art Unit 1621 and has examined 56 patent applications in our dataset. With an allowance rate of 46.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner SCHMIDT, IZABELA MARIA's allowance rate of 46.4% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SCHMIDT, IZABELA MARIA receive 1.14 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SCHMIDT, IZABELA MARIA is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +67.8% benefit to allowance rate for applications examined by SCHMIDT, IZABELA MARIA. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.3% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 27.3% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.7% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.